Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Barinthus Biotherapeutics (BRNS)
NASDAQ:BRNS
RESEARCH TOOLSreports
Barinthus Biotherapeutics (BRNS) Stock Price & Analysis
73 Followers
BRNS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.21 - $5.10
Previous Close$1.4
Volume14.25K
Average Volume (3M)24.51K
Market Cap
$56.29M
Enterprise Value-$74.37M
Total Cash (Recent Filing)$142.09M
Total Debt (Recent Filing)$12.98M
Price to Earnings (P/E)―
Beta0.70
Next Earnings
Aug 08, 2024EPS Estimate
-$0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding39,033,158
10 Day Avg. Volume26,812
30 Day Avg. Volume24,506
Standard Deviation0.19
R-Squared0.01
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)0.34
Price to Sales (P/S)64.24
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-10.25
Enterprise Value/Gross Profit-92.73
Enterprise Value/Ebitda1.23
Forecast
1Y Price Target
$6.33Price Target Upside338.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Barinthus Biotherapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsInterim data from the HBV003 trial showed sustained HBsAg decline in patients treated with VTP-300 and low-dose nivolumab.
Operational EfficiencyThe company plans to reduce workforce by roughly 25% to streamline operations for the prioritized pipeline, which would extend cash runway into 2Q26.
Regulatory ApprovalsBarinthus has received clearance from the U.S. FDA and the Australian Ethics Committee to advance VTP-1000 into a first-in-human Phase 1 GLU001 trial in celiac disease.
Bears Say
EarningsThe net impact of model changes brings EPS estimates to -$1.58 / -$1.21 / -$1.11 from -$1.45.
Product PerformanceHPV data in April fell short of the company’s own hurdle, raising doubts on VTP-200 future.
Regulatory RisksRisks include failure of therapeutic candidates in clinical trials and failure to secure regulatory approval.
---
Ownership Overview
39.51%
Insiders
0.03% Mutual Funds
13.37% Other Institutional Investors
47.09% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
BRNS FAQ
What was Barinthus Biotherapeutics’s price range in the past 12 months?
Barinthus Biotherapeutics lowest stock price was $1.21 and its highest was $5.10 in the past 12 months.
What is Barinthus Biotherapeutics’s market cap?
Currently, no data Available
When is Barinthus Biotherapeutics’s upcoming earnings report date?
Barinthus Biotherapeutics’s upcoming earnings report date is Aug 08, 2024 which is in 17 days.
How were Barinthus Biotherapeutics’s earnings last quarter?
Barinthus Biotherapeutics released its earnings results on May 13, 2024. The company reported -$0.4 earnings per share for the quarter, beating the consensus estimate of -$0.544 by $0.144.
Is Barinthus Biotherapeutics overvalued?
According to Wall Street analysts Barinthus Biotherapeutics’s price is currently Undervalued.
Does Barinthus Biotherapeutics pay dividends?
Barinthus Biotherapeutics does not currently pay dividends.
What is Barinthus Biotherapeutics’s EPS estimate?
Barinthus Biotherapeutics’s EPS estimate is -$0.4.
How many shares outstanding does Barinthus Biotherapeutics have?
Barinthus Biotherapeutics has 39,033,157 shares outstanding.
What happened to Barinthus Biotherapeutics’s price movement after its last earnings report?
Barinthus Biotherapeutics reported an EPS of -$0.4 in its last earnings report, beating expectations of -$0.544. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Barinthus Biotherapeutics?
Currently, no hedge funds are holding shares in BRNS
---
Barinthus Biotherapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.33 (338.06% Upside)
$6.33 (338.06% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 5.6%
Last 30 Days ▼ 5.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-36.36%
12-Months-Change
Fundamentals
Return on Equity
-34.95%
Trailing 12-Months
Asset Growth
-23.81%
Trailing 12-Months
Company Description
Barinthus Biotherapeutics
Vaccitech PLC is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. Its therapeutic programs include VTP-300, VTP-200, VTP-850, and VTP-600. Its current prophylactic programs include VTP-400. In addition, it also co-invented a COVID-19 vaccine candidate with the University of Oxford known as COVID-19 Vaccine AstraZeneca.
---
BRNS Stock 12 Month Forecast
Average Price Target
$6.33
▲(338.06% Upside)
Technical Analysis
Best Analysts Covering BRNS
1 Year
1 Year Success Rate
2/18 ratings generated profit
1 Year Average Return
-32.61%
reiterated a buy rating last month
Copying Yi Chen's trades and holding each position for 1 Year would result in 11.11% of your transactions generating a profit, with an average return of -32.61% per trade.
---